CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,011 enrolled
Drug / intervention
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets +1 moredrug
Likely dose
olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00430950
NCT00430950Phase 3Completed
CompareCT.gov

Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy

Daiichi Sankyo·interventional·Posted Feb 2, 2007·Updated Jan 10, 2019

In Brief

A Phase 3 clinical trial evaluating olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets and olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg for Essential Hypertension. Completed, enrolled 1,011 participants across 41 sites in 4 countries.

Detailed Summary

The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesBelgium, Germany, Netherlands, Slovakia
CollaboratorsDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2007
Enrollment StartFeb 1, 2007
Primary CompletionMay 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.4 years ago

Interventions

olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tabletsdrug

olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks

olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mgdrug

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks